The second method uses CD34+/CD133+ biomarkers that are less specific for EPCs; CD133 is a stem cell marker that is not only present on immature endothelial progenitor cells, but is also found on other cell types such as epithelial cells and cancer stem cells. Here, PROM1 is linked to cancer.